Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the latent HIV reservoir, which is the virus hiding in the blood of people living with HIV, even when their infection is under control with antiretroviral therapy ART. This reservoir is a major obstacle to curing HIV. The study focuses on Ugandans with HIV who have suppressed viral loads, aiming to measure the reservoir size and understand factors affecting it. This knowledge may help develop new strategies to prevent or control HIV. The study involves four groups of participants those on ART with suppressed viral loads, those with a known recent infection window, those with suppressed viral loads not on ART, and those who started ART early after infection. Participants will have yearly visits over 20 years, including fingerstick hemoglobin screening and blood draws. Blood samples will be analyzed for viral latency, immune responses, and other markers to track changes in the latent reservoir over time. Participants will undergo medical history reviews, physical exams, and questionnaires about their health. Researchers will monitor viral loads, immune activation, and other factors related to HIV latency. Blood will be tested for other diseases and pregnancy when applicable. The studys long-term follow-up will help understand the decay and formation rates of the latent HIV reservoir in this population, comparing findings to Western cohorts.
Actively Recruiting
Healthy Volunteer
Researchers are studying the impact of integrating female curable sexually transmitted infection cSTI testing with self-reported risk screening tools SRST to improve pre-exposure prophylaxis PrEP use among cis-gender African women aged 15 to 39 years. The study aims to address the challenge that many women at high risk for HIV are not identified by current screening methods and that PrEP use often declines shortly after initiation. This research is nested within the Rakai Community Cohort Study in Uganda, focusing on HIV prevention and control in a high-burden region. Participants will be randomly assigned to one of two groups one receiving standard self-reported risk screening plus diagnostic testing for chlamydia, gonorrhea, trichomonas, and syphilis, and the other receiving self-reported risk screening alone. Both groups will have access to syndromic case management for STIs and syphilis testing for pregnant women. Women who test positive for cSTIs or meet PrEP eligibility based on screening will be referred for same-day PrEP initiation and provided free treatment for themselves and their partners if diagnosed with an STI. During the study, participants will be evaluated for PrEP uptake, adherence, and persistence up to six months after enrollment through surveys, clinical records, and drug level testing. Additional qualitative interviews will explore factors influencing PrEP use and cSTI testing implementation. Mathematical modeling will assess optimal cSTI testing strategies for reducing HIV incidence and improving population health. The total study duration extends through 2029, with primary outcomes measured up to six months after enrollment.